China is currently the world's second-largest market forpharmaceuticals behind the United States, and it continues to growat a very strong pace. Pfizer is well-positioned to take advantageof this growth; China represents one of the company'sfastest-growing markets around the globe.

“Our business in China has done extremely well in recent years,”says John Sweetman, Pfizer's treasury director for the Asia-Pacific(APAC) region. “We're very excited about our growth prospects infuture years as well.”

Continue Reading for Free

Register and gain access to:

  • Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
  • Informative weekly newsletter featuring news, analysis, real-world cas studies, and other critical content
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Meg Waters

Meg Waters is the editor in chief of Treasury & Risk. She is the former editor in chief of BPM Magazine and the former managing editor of Business Finance.